Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001748
UniProt IDP53582
Primary gene name(s)METAP1
Synonym gene name(s)KIAA0094
Protein nameMethionine aminopeptidase 1
Protein functionCotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged, Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val. Required for normal progression through the cell cycle. {ECO:0000255|HAMAP-Rule:MF_03174, ECO:0000269|PubMed:16274222, ECO:0000269|PubMed:17114291}.
Subcellular locationCytoplasm {ECO:0000255|HAMAP-Rule:MF_03174}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P53582
Gene Ontology
(Biological Process)
Complete annatation
N-terminal protein amino acid modification [GO:0031365];
peptidyl-methionine modification [GO:0018206];
platelet aggregation [GO:0070527];
protein initiator methionine removal [GO:0070084];
regulation of rhodopsin mediated signaling pathway [GO:0022400];
regulation of translation [GO:0006417]
Gene Ontology
(Molecular Function)
Complete annatation
aminopeptidase activity [GO:0004177];
metal ion binding [GO:0046872];
metalloexopeptidase activity [GO:0008235]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
nucleus [GO:0005634]
Protein-protein interaction116785
Phylogenetic treeP53582
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.3602512259900010.2724264829509940.387835265045563
AZA vs. DISU0.01269480945239840.9600670288322740.996649735504266
AZA vs. IL70.1228583584850090.5243295421237140.999311006273513
AZA vs. SAHA-0.3271361319279880.1823263122508770.545098538450955
DISU vs. CD3-0.3598087116383030.3210872108474580.454040207909436
DISU vs. IL70.1010095243935370.6887647069359340.91804885048312
DISU vs. SAHA-0.3384313778282950.2464628970272370.624704935827561
DMSO vs. AZA-0.01734252684274690.9179779577884621
DMSO vs. CD3-0.3878966095464140.2260433919004530.329464367161409
DMSO vs. DISU-0.03158837629069950.8971784721792120.988283279918411
DMSO vs. IL70.1473083639447890.414355324268040.849620037179095
DMSO vs. SAHA-0.3165942918380630.1813215777995390.513954767541254
HIV vs. Mock in Activation0.06134073922983170.9215361569436550.999983755607037
HIV vs. Mock in Latency0.02219909676759250.893533299083610.999834320637052
IL7 vs. CD3-0.229957575082780.4742025831948220.606195872826355
SAHA vs. CD3-0.7114534195501670.0450223576903310.0909987835827908
SAHA vs. IL7-0.4533205374155630.06381716994751640.215952632807678
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.286771 0.0276955
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.031 0.866 0.898 0.989 0.908
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB07901 5-CHLORO-6-METHYL-N-(2-PHENYLETHYL)-2-PYRIDIN-2-YLPYRIMIDIN-4-AMINE experimental unknown unknown
DB07902 TERT-BUTYL {2-[(1,3-THIAZOL-2-YLAMINO)CARBONYL]PYRIDIN-3-YL}CARBAMATE experimental unknown unknown
DB07903 3-[(2,2-DIMETHYLPROPANOYL)AMINO]-N-1,3-THIAZOL-2-YLPYRIDINE-2-CARBOXAMIDE experimental unknown unknown
DB04324 Ovalicin experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
2B3H X-ray 1.1Å A=81-384.
2B3K X-ray 1.5Å A=81-384.
2B3L X-ray 1.5Å A=81-384.
2G6P X-ray 1.9Å A=81-384.
2GZ5 X-ray 1.1Å A=81-384.
2NQ6 X-ray 1.5Å A=81-384.
2NQ7 X-ray 1.6Å A=81-384.
4FLI X-ray 1.5Å A=81-386.
4FLJ X-ray 1.7Å A=81-386.
4FLK X-ray 1.4Å A=81-386.
4FLL X-ray 1.5Å A=81-386.
4HXX X-ray 2.0Å A=81-384.
4IKR X-ray 1.7Å A=81-384.
4IKS X-ray 1.7Å A=81-384.
4IKT X-ray 1.6Å A=81-384.
4IKU X-ray 1.3Å A=81-384.
4IU6 X-ray 1.9Å A=1-384.
4U1B X-ray 1.8Å A=81-386.
4U69 X-ray 1.6Å A=81-386.
4U6C X-ray 1.9Å A=81-386.
4U6E X-ray 1.9Å A=81-386.
4U6J X-ray 1.5Å A=81-386.
4U6W X-ray 1.8Å A=81-386.
4U6Z X-ray 1.8Å A=81-386.
4U70 X-ray 1.6Å A=81-386.
4U71 X-ray 1.8Å A=81-386.
4U73 X-ray 1.8Å A=81-386.
4U75 X-ray 1.9Å A=81-386.
4U76 X-ray 1.8Å A=81-386.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
not found